



Supplementary material has been published as submitted. It has not been copyedited, typeset or checked for scientific content by Acta Dermato-Venereologica


Supplemental Figure 1: Result of meta-analysis for SALT30, regarding treatment with brepocitinib and ritlecitinib.




Supplemental Figure 2: Result of meta-analysis for SALT50, regarding treatment with baricitinib, brepocitinib and ritlecitinib.




Supplemental Figure 3: Result of meta-analysis for SALT75, regarding treatment with baricitinib, brepocitinib and ritlecitinib.




Supplemental Figure 4: Result of meta-analysis for SALT90, regarding treatment with baricitinib, brepocitinib and ritlecitinib.




Supplemental Figure 5: Result of meta-analysis for SALT100, regarding treatment with baricitinib, brepocitinib and ritlecitinib.



Supplemental Figure 6: Result of meta-analysis for SALT50, regarding treatment with CTP-543 (deuruxolitinib), and baricitinib.



Supplemental Figure 7: Result of meta-analysis for SALT75, regarding treatment with CTP-543 (deuruxolitinib), and baricitinib.



Supplemental Figure 8: Result of meta-analysis for SALT90, regarding treatment with CTP-543 (deuruxolitinib), and baricitinib.

